ACRX Shares Outstanding History
Below is a table of the ACRX shares outstanding history going back to 2/4/2011:

Date ACRX Shares Outstanding
2/4/201116.13M
3/29/201119.37M
5/1/201119.37M
8/1/201119.42M
11/1/201119.55M
1/31/201219.57M
5/1/201219.69M
7/1/201222.62M
10/15/201222.65M
1/31/201337.06M
4/25/201337.24M
7/30/201342.12M
10/15/201343.04M
2/25/201443.18M
4/17/201443.32M
7/21/201443.38M
10/24/201443.71M
2/25/201543.71M
4/22/201544.34M
7/21/201544.37M
10/21/201544.45M
2/24/201645.27M
4/21/201645.31M
7/21/201645.31M
10/21/201645.33M
2/23/201745.34M
4/27/201745.38M
7/26/201745.38M
10/25/201750.34M
2/26/201850.90M
5/7/201851.32M
7/26/201860.60M
10/30/201861.91M
2/25/201978.76M
4/18/201978.89M
5/2/201978.91M

Also see: ACRX Market Cap History
and ACRX YTD Return
ACRX Historical Shares Outstanding:
+21.24% CAGR
ACRX Historical Shares Outstanding: +21.24% CAGR

Mouse over chart for data details
2/4/2011 ...5/2/2019
AcelRx Pharmaceuticals is a pharmaceutical company. Co.'s product candidates, focused on the treatment of acute pain are, DSUVIA™ (known as DZUVEO outside of the U.S.), and ZALVISO®, each of which utilizes sublingual sufentanil, delivered via a non-invasive route of sublingual administration, for use in medically supervised settings. DSUVIA is a non-invasive investigational product candidate consisting of sufentanil tablets delivered sublingually by a healthcare personnel using a disposable, pre-filled, single-dose applicator. ZALVISO consists of sufentanil sublingual tablets delivered by the ZALVISO System, a needle-free, handheld, patient-administered, pain management system. We show 36 historical shares outstanding datapoints in our coverage of ACRX's shares outstanding history.

Understanding the changing numbers of ACRX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ACRX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ACRX by allowing them to research ACRX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for ACRX:
ACRX SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
AcelRx Pharmaceuticals (ACRX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ACST Shares Outstanding History
ADMA Shares Outstanding History
ADMP Shares Outstanding History
ADMS Shares Outstanding History
ADRO Shares Outstanding History
ADUS Shares Outstanding History
ADVM Shares Outstanding History
ADXS Shares Outstanding History
AEMD Shares Outstanding History
AERI Shares Outstanding History
More Healthcare companies »

 

ACRX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.